How Should We Evaluate Outcomes for Use of Biologics in the Knee?
J Knee SurgDOI: 10.1055/s-0034-1390028In recent years, the use of biologics for the primary treatment and augmentation of treatment in patients with knee pathology has increased substantially. Techniques and applications for biologic preparations such as platelet-rich plasma (PRP) and mesenchymal stem cells (MSCs) have been developed and refined to increase the healing response in bone, ligaments, cartilage, meniscal tissue, and other areas of the knee. Beginning with basic science and animal models, and finally proceeding to clinical human trials, the effect of biologics on clinical outcomes has been widely studied; however, many results have been inconclusive on their true effectiveness. The purpose of this article is to review current strategies for evaluating outcomes after biologic treatment and to propose new recommendations for assessing outcomes following the use of biologics in the knee. In addition, the importance of study design, current challenges, and future directions will be reviewed to describe the current standards for future studies to follow.[...]Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.Article in Thieme eJournals:Table of contents | Abstract | Full text
ConclusionsThe increase in a number of genes associated with ribosome biogenesis, translation, and mTOR signaling may be important to evaluate prognosis and determine treatment approach for prostate cancer (PCa). A better understanding of the molecular pathways associated with CSCs may be promising to develop targeted therapies to prolong survival in PCa.
Publication date: Available online 28 May 2020Source: Stem Cell ResearchAuthor(s): Marga J. Bouma, Valeria Orlova, Francijna E. van den Hil, Hans-Jurgen Mager, Frank Baas, Peter de Knijff, Christine L. Mummery, Harald Mikkers, Christian Freund
Publication date: Available online 28 May 2020Source: Stem Cell ResearchAuthor(s): Lara Schöning, Niki Tomas Loges, Yvonne Nitschke, Inga Höben, Albrecht Röpke, Laura Crisponi, Heymut Omran, Frank Rutsch, Insa Buers
Publication date: Available online 28 May 2020Source: Stem Cell ReportsAuthor(s): Olga Iendaltseva, Valeria V. Orlova, Christine L. Mummery, Erik H.J. Danen, Thomas Schmidt
Publication date: Available online 28 May 2020Source: Stem Cell ReportsAuthor(s): Akihiro Yamaguchi, Kei-ichi Ishikawa, Tsuyoshi Inoshita, Kahori Shiba-Fukushima, Shinji Saiki, Taku Hatano, Akio Mori, Yutaka Oji, Ayami Okuzumi, Yuanzhe Li, Manabu Funayama, Yuzuru Imai, Nobutaka Hattori, Wado Akamatsu
Pack Health is participating in a pilot study with the University of California San Francisco Helen Diller Family Comprehensive Cancer Center. For Pack Health, it's the latest in a series of notable partnerships for the Birmingham-based firm. The study intends to use digital coaching to support individuals with multiple myeloma who are undergoing stem cell transplantation. “We are excited to expand the role of digital coaching to this unique patient population for whom the transplantation…
Chem. Commun., 2020, Accepted Manuscript DOI: 10.1039/D0CC03403G, CommunicationAlessia Battigelli, Bethany Almeida, Shashank Shukla, Alicia Dolores Rocha, Anita Shukla We introduce an innovative approach to adhere mesenchymal stem cells (MSCs) to a hydrogel scaffold by nucleating adhesion through strain-promoted click chemistry. This method yields a significant increase in cell... The content of this RSS Feed (c) The Royal Society of Chemistry
Authors: Lee SS, McCue D, Pemmaraju N Abstract INTRODUCTION: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematologic malignancy that previously lacked standardized therapeutic approaches. CD123 (interleukin-3 receptor alpha unit) is highly expressed in many hematologic malignancies, including BPDCN. Tagraxofusp-ezrs (tagraxofusp from herein) is an agent that consists of interleukin-3 fused to a truncated diphtheria toxin, targeting CD123. The Food and Drug Administration recently approved tagraxofusp as therapy for BPDCN for adults and children aged 2 years and older. AREAS COVERE...
Authors: Sun YQ, Li SQ, Zhao XS, Chang YJ Abstract INTRODUCTION: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a curable strategy for acute lymphoblastic leukemia (ALL), especially for adult cases. However, leukemia relapse after allograft restricts the improvement of transplant outcomes. Measurable residual disease (MRD) has been the strongest predictor for relapse after allo-HSCT, allowing MRD-directed preemptive therapy. AREAS COVERED: This manuscript summarizes the detection of MRD in patients with ALL who undergo allo-HSCT, focusing the effects of positive pre-HSCT MRD and post-HSC...
Publication date: Available online 28 May 2020Source: MethodsAuthor(s): Prakhar Mishra, Richard I. Cohen, Nanxia Zhao, Prabhas V. Moghe